Exelixis Provides Update on ODAC Panel for Cabozantinib
17:01 EDT 29 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Exelixis, Inc. (NASDAQ: EXEL) today was notified by the Food and Drug
Administration (the “FDA”) that the Company’s new drug application
(“NDA”) for cabozantinib as a treatment for patients with progressive,
unresectab...
Other Sources for this Article
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations and Corporate Communications
cbutler@exelixis.com
More From BioPortfolio on "Exelixis Provides Update on ODAC Panel for Cabozantinib"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
